Out Of The Ashes: Roche’s Dalcetrapib Data Suggest Still Hope For CETP Inhibitor Class
Executive Summary
Experts see various reasons why Roche’s HDL-raising drug may have failed to demonstrate benefit in the dal-OUTCOMES study, including insufficient potency resulting from only partial CETP inhibition. Final word on the class’ fate likely will not be written until outcomes studies by Merck and Lilly report out in several years.
You may also be interested in...
Big REVEAL: Merck's Anacetrapib Surprises With Success, But What Next?
The positive top-line results for Merck & Co's cardiovascular outcomes trial for its CETP inhibitor anacetrapib may not be enough to de-risk the class, and questions remain about the level of clinical benefit and the regulatory options.
Who Suffers From Lilly's Evacetrapib Failure?
Lilly hits a late-stage snag that causes worries about its pipeline potential and has repercussions for several other companies working in the cholesterol space.
Dezima Pharma Raises $18.6 Million For Next-Generation CETP Inhibitor
Dutch start-up Dezima Pharma raises $18.6 million in Series A funding and government loans to move a next-generation CETP inhibitor to Phase III.